2002
DOI: 10.1590/s1413-86702002000300001
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Linezolid was the first clinically applied member of the new antimicrobial class called the oxazolidinones. These agents have a powerful spectrum of activity focussed against Gram-positive organisms including strains with documented resistances to other antimicrobial classes. We conducted a multicenter surveillance (Zyvox Antimicrobial Potency Study; ZAPS) trial of qualifying Gram-positive isolates from 24 medical centers in eight countries in Latin America. The activity and spectrum of linezolid was compared … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
4
0
1

Year Published

2004
2004
2009
2009

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 16 publications
(6 citation statements)
references
References 28 publications
1
4
0
1
Order By: Relevance
“…These data support and extend the previous findings from the premarketing ZAPS studies [14][15][16][17][18] and the 2002 ZAAPS Program [13]. The overall linezolid resistance rate for 2003 was only 0.07%, which was similar to the 2002 statistic (0.05%) as well as the rate cited in an independently reported surveillance study (0.07%) [12].…”
Section: Resultssupporting
confidence: 87%
See 3 more Smart Citations
“…These data support and extend the previous findings from the premarketing ZAPS studies [14][15][16][17][18] and the 2002 ZAAPS Program [13]. The overall linezolid resistance rate for 2003 was only 0.07%, which was similar to the 2002 statistic (0.05%) as well as the rate cited in an independently reported surveillance study (0.07%) [12].…”
Section: Resultssupporting
confidence: 87%
“…Table 2 provides a summary of the organisms tested against linezolid and the comparator antimicrobial agents. The activity of linezolid against staphylococci proved to be exceptional in 2003 and nearly identical to that found in the 2002 ZAAPS Program (Table 3) [13] and the pre-marketing ZAPS data [14][15][16][17][18]. The linezolid MIC 90 and modal MIC for S. aureus and CoNS were 2 and 1 mg/L, respectively, with all isolates categorised as susceptible [20].…”
Section: Antimicrobial Usagementioning
confidence: 60%
See 2 more Smart Citations
“…In the laboratory, strains of linezolid-resistant enterococci have been generated by serial passage of clinical VRE isolates by using doubling dilutions of linezolid; linezolid resistance was associated with mutations in the domain V region of the 23S rRNA gene (21). Clinical infections by linezolid-resistant Enterococcus species have been reported at individual centers (2, 9, 11, 13) but have been rare in the United States and internationally (3,4,6). The true frequency of linezolid-resistant enterococcal infections may be underestimated, because many laboratories do not routinely test enterococccal isolates for linezolid susceptibility.…”
Section: Case Reportmentioning
confidence: 99%